FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

BRATTON DOUGLAS K 		2. Issuer Name and Ticker or Trading Symbol

Juno Therapeutics, Inc. [ JUNO ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

201 MAIN STREET, SUITE 1900 		3. Date of Earliest Transaction (MM/DD/YYYY)

7/13/2017
(Street)

FORT WORTH, TX 76102
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   7/13/2017     S    8000000   (1) D $27.00   9166130   I   By CL Alaska, L.P.   (2) (3)
Common Stock                  182669   I   By JT Line Partners LP   (4)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  The purchase reported in Column 4 occurred in a block transaction at a price of $27.00 per share.
(2)  These 9,166,130 shares of the Issuer are held directly by CL Alaska, L.P. ("CLA"). The general partner of CLA is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of CLA is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. CLA is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all of these shares of the Issuer as well as a partial pecuniary interest in the shares held by CLA. Mr. Bratton does not intend to sell additional shares of the Issuer from CLA at this time, however, please see the related disclosures in Item 4 of the Schedule 13D/A filed on June 25, 2015.
(3)  (Continued from footnote 2) CLA may be deemed to directly beneficially own all of these shares of the Issuer. Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to indirectly beneficially own all of these shares of the Issuer. Each such entity and Mr. Bratton disclaims beneficial ownership of these shares, except to the extent of its or his respective pecuniary interest therein.
(4)  The shares of the Issuer reported in Column 5 are held directly by JT Line Partners LP ("JT"). The general partner of JT is Bratton Capital Management L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. JT is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all of the shares of the Issuer held by JT, as well as a partial pecuniary interest in such shares. JT directly beneficially owns these shares of the Issuer. Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to indirectly beneficially own the shares of the Issuer held by JT. Each such entity and Mr. Bratton disclaims beneficial ownership of these shares, except to the extent of its or his respective pecuniary interest therein.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
BRATTON DOUGLAS K
201 MAIN STREET, SUITE 1900
FORT WORTH, TX 76102
X

Crestline Investors, Inc.
201 MAIN STREET, SUITE 1900
FORT WORTH, TX 76102
X

Crestline SI (GP), L.P.
201 MAIN STREET, SUITE 1900
FORT WORTH, TX 76102
X

Crestline Management, LP
201 MAIN STREET, SUITE 1900
FORT WORTH, TX 76102
X

CL Alaska, L.P.
201 MAIN STREET, SUITE 1900
FORT WORTH, TX 76102
X


Signatures
/s/ Douglas K. Bratton 7/17/2017
** Signature of Reporting Person Date

/s/ John S. Cochran, Vice President of Crestline Investors, Inc. 7/17/2017
** Signature of Reporting Person Date

/s/ John S. Cochran, Vice President of Crestline Investors, Inc., general partner of Crestline SI (GP), L.P. 7/17/2017
** Signature of Reporting Person Date

/s/ John S. Cochran, Vice President of Crestline Investors, Inc., general partner of Crestline Management, L.P. 7/17/2017
** Signature of Reporting Person Date

/s/ John S. Cochran, Vice President of Crestline Investors, Inc., general partner of Crestline SI (GP), L.P., general partner of CL Alaska, L.P. 7/17/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
JUNO THERAPEUTICS, INC. (NASDAQ:JUNO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more JUNO THERAPEUTICS, INC. Charts.
JUNO THERAPEUTICS, INC. (NASDAQ:JUNO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more JUNO THERAPEUTICS, INC. Charts.